Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.

• Ngā kaituhi matua: Jason W Bennett (Author), Anjali Yadava (Author), Donna Tosh (Author), Jetsumon Sattabongkot (Author), Jack Komisar (Author), Lisa A Ware (Author), William F McCarthy (Author), Jessica J Cowden (Author), Jason Regules (Author), Michele D Spring (Author), Kristopher Paolino (Author), Joshua D Hartzell (Author), James F Cummings (Author), Thomas L Richie (Author), Joanne Lumsden (Author), Edwin Kamau (Author), Jittawadee Murphy (Author), Cynthia Lee (Author), Falgunee Parekh (Author), Ashley Birkett (Author), Joe Cohen (Author), W Ripley Ballou (Author), Mark E Polhemus (Author), Yannick F Vanloubbeeck (Author), Johan Vekemans (Author), Christian F Ockenhouse (Author)
• Hōputu: Pukapuka
• I whakaputaina: Public Library of Science (PLoS), 2016-02-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

A vaccine to prevent infection and disease caused by Plasmodium vivax is needed both to reduce the morbidity caused by this parasite and as a key component in efforts to eradicate malaria worldwide. Vivax malaria protein 1 (VMP001), a novel chimeric protein that incorporates the amino- and carboxy-...